OPKO Health (OPK)
(Real Time Quote from BATS)
$1.23 USD
-0.02 (-1.60%)
Updated Apr 24, 2024 12:06 PM ET
4-Sell of 5 4
C Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OPK 1.23 -0.02(-1.60%)
Will OPK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for OPK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OPK
OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
OPK: What are Zacks experts saying now?
Zacks Private Portfolio Services
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say
Other News for OPK
Notable open interest changes for April 11th
Notable open interest changes for April 10th
Largest borrow rate increases among liquid names
Opko Health Buy Rating Backed by Strategic Asset Sale and Promising Oral Drug Candidate
Critical Insights From OPKO Health Analyst Ratings: What You Need To Know